Holen Sie sich die Stockscreener-App
63.46
1.04%
-0.67
Schlusskurs vom Vortag:
$64.13
Offen:
$64.81
24-Stunden-Volumen:
900.48K
Relative Volume:
0.69
Marktkapitalisierung:
$5.30B
Einnahmen:
$1.73B
Nettoeinkommen (Verlust:
$682.64M
KGV:
8.2028
EPS:
7.7364
Netto-Cashflow:
$411.18M
1W Leistung:
+1.26%
1M Leistung:
-11.60%
6M Leistung:
-6.36%
1J Leistung:
+0.70%
1-Tages-Spanne:
$62.80
$65.39
1-Wochen-Bereich:
$62.30
$66.26
52-Wochen-Spanne:
$61.23
$90.87
Ptc Therapeutics Inc Stock (PTCT) Company Profile
Firmenname
Ptc Therapeutics Inc
Sektor
Branche
Telefon
(908) 222-7000
Adresse
500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ
Compare PTCT vs VRTX, MRNA, REGN, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PTCT
Ptc Therapeutics Inc
|
63.46 | 5.23B | 1.73B | 682.64M | 411.18M | 7.7364 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ptc Therapeutics Inc Stock (PTCT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-10 | Eingeleitet | Raymond James | Outperform |
| 2026-01-28 | Fortgesetzt | Barclays | Overweight |
| 2025-12-01 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-10-20 | Eingeleitet | Wells Fargo | Overweight |
| 2025-06-17 | Eingeleitet | Truist | Buy |
| 2025-05-09 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-05-07 | Hochstufung | Citigroup | Sell → Neutral |
| 2025-03-11 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Perform |
| 2024-12-13 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-03 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-09-04 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-08-26 | Fortgesetzt | UBS | Buy |
| 2024-05-20 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2023-12-19 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2023-10-30 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2023-10-27 | Herabstufung | Citigroup | Neutral → Sell |
| 2023-10-06 | Herabstufung | Truist | Buy → Hold |
| 2023-09-18 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-09-15 | Herabstufung | Raymond James | Outperform → Underperform |
| 2023-03-17 | Eingeleitet | SVB Securities | Market Perform |
| 2022-12-14 | Eingeleitet | Goldman | Sell |
| 2022-09-12 | Eingeleitet | Jefferies | Buy |
| 2022-09-09 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-09-01 | Eingeleitet | Citigroup | Buy |
| 2022-04-04 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2021-10-18 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Neutral |
| 2021-03-29 | Hochstufung | RBC Capital Mkts | Underperform → Sector Perform |
| 2021-02-12 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-01-05 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-11-30 | Herabstufung | RBC Capital Mkts | Sector Perform → Underperform |
| 2020-10-30 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-10-07 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-08-25 | Eingeleitet | Raymond James | Outperform |
| 2020-04-09 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-02-20 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-02-20 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-05-13 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-04-11 | Eingeleitet | Bernstein | Outperform |
| 2018-10-03 | Hochstufung | BofA/Merrill | Underperform → Neutral |
| 2018-10-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-07-19 | Eingeleitet | Credit Suisse | Outperform |
| 2018-06-18 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-04-04 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2018-01-29 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2017-11-16 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2017-10-26 | Herabstufung | BofA/Merrill | Neutral → Underperform |
| 2017-10-09 | Herabstufung | JP Morgan | Neutral → Underweight |
Alle ansehen
Ptc Therapeutics Inc Aktie (PTCT) Neueste Nachrichten
A director proposes selling $782K in option-exercised PTC Therapeutics (PTCT) shares. - Stock Titan
Non-controlling/minority interest of PTC Therapeutics, Inc. – HAN:BH3 - TradingView
PTC Therapeutics, Inc. (PTCT) Stock Price, News, Quote & History - Yahoo! Finance Canada
PTC Therapeutics (NASDAQ:PTCT) Stock Price Up 4.7%Here's What Happened - MarketBeat
37 new hires get options to buy PTC shares at $65.96 - Stock Titan
PTC Therapeutics, Inc. (PTCT) Stock Forecasts - Yahoo! Finance Canada
PTC Therapeutics stock gets a Fabry therapy catalyst - AD HOC NEWS
PTC Therapeutics stock rises as third quarter data strengthen outlook - AD HOC NEWS
(PTCT) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Cantor raises PTC Therapeutics stock price target on Fabry deal By Investing.com - Investing.com Canada
Cantor Fitzgerald Boosts PTC Therapeutics (NASDAQ:PTCT) Price Target to $137.00 - MarketBeat
Cantor Fitzgerald maintains Overweight rating on PTC Therapeutics, $137 price target - TradingView
PTC Therapeutics completes ST-920 gene therapy acquisition By Investing.com - Investing.com India
PTC Therapeutics completes ST-920 gene therapy acquisition - Investing.com
PTC Therapeutics Closes Acquisition of the ST-920 Gene Therapy for Fabry Disease - Yahoo Finance
PTC Completes Acquisition of ST-920, BLA Submission Expected in Q4 2026 - TradingView
A one-time gene therapy for Fabry disease is now PTC’s. FDA filing expected later in 2026. - Stock Titan
PTC Completes Acquisition of ST-920 Fabry Disease Gene Therapy - Yahoo Finance
PTC Therapeutics (PTCT) Could Be 36% Undervalued Following Pipeline Progress - Yahoo Finance
Bank of America Corp DE Takes $118.46 Million Position in PTC Therapeutics, Inc. $PTCT - MarketBeat
PTC Therapeutics director Schmertzler sells $1.35m shares - Investing.com
Wall Street Zen Upgrades PTC Therapeutics (NASDAQ:PTCT) to "Strong-Buy" - MarketBeat
PTC Therapeutics director Schmertzler sells $1.35m shares By Investing.com - Investing.com Nigeria
PTC Therapeutics (NASDAQ:PTCT) Director Sells 10,000 Shares - MarketBeat
PTC Therapeutics Director Michael Schmertzler Executes 20,000 Share Sale Under 10b5-1 Trading Plan - Kalkine Media
PTC Therapeutics (NASDAQ: PTCT) director offloads 20,000 shares under trading plan - Stock Titan
Is PTC Therapeutics (PTCT) Undervalued After Its Recent Pullback? - simplywall.st
ETFs Investing in PTC Therapeutics, Inc. Stocks - TradingView
PTC Therapeutics at Morgan Stanley conference: sephience drives outlook By Investing.com - Investing.com Nigeria
PTC Therapeutics, Inc. $PTCT Shares Sold by Engineers Gate Manager LP - MarketBeat
California State Teachers Retirement System Lowers Holdings in PTC Therapeutics, Inc. $PTCT - MarketBeat
PTC Therapeutics, Inc. (NASDAQ:PTCT) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Leerink Partners Begins Coverage on PTC Therapeutics (NASDAQ:PTCT) - MarketBeat
(PTCT) Volatility Zones as Tactical Triggers - Stock Traders Daily
PTC Therapeutics director Schmertzler sells $1.35m in stock - investing.com
PTC Therapeutics director Schmertzler sells $1.35m in stock By Investing.com - Investing.com India
Insider Selling: PTC Therapeutics (NASDAQ:PTCT) Director Sells 10,000 Shares of Stock - MarketBeat
Director stock sale at PTC Therapeutics (PTCT) ran on a preset 10b5-1 plan - Stock Titan
PTC Therapeutics at cantor healthcare conference: sephience drives growth By Investing.com - Investing.com Canada
VIRGINIA RETIREMENT SYSTEMS ET Al Invests $2.32 Million in PTC Therapeutics, Inc. $PTCT - MarketBeat
PTC Therapeutics at Wells Fargo conference: sufiance drives growth plan By Investing.com - Investing.com Canada
Hsbc Holdings PLC Reduces Holdings in PTC Therapeutics, Inc. $PTCT - MarketBeat
PTC Therapeutics at Wells Fargo conference: Sephience drives growth plan - Investing.com
Director-affiliated fund at PTC Therapeutics (NASDAQ: PTCT) plans another stock sale - Stock Titan
Corient Private Wealth LP Makes New Investment in PTC Therapeutics, Inc. $PTCT - MarketBeat
PTC Therapeutics (PTCT) Moves 7.2% Higher: Will This Strength Last? - Eastern Progress
Wells Fargo Sticks to Its Buy Rating for PTC Therapeutics (PTCT) - theglobeandmail.com
Wells Fargo Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Maintains Target Price $109 - moomoo.com
Moore Capital Management LP Acquires 30,894 Shares of PTC Therapeutics, Inc. $PTCT - MarketBeat
Wellington Management Group LLP Raises Stake in PTC Therapeutics, Inc. $PTCT - MarketBeat
Empowered Funds LLC Acquires Shares of 81,271 PTC Therapeutics, Inc. $PTCT - MarketBeat
Finanzdaten der Ptc Therapeutics Inc-Aktie (PTCT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Ptc Therapeutics Inc-Aktie (PTCT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| STEELE GLENN JR MD PHD | Director |
Sep 30 '26 |
Sale |
65.16 |
12,000 |
781,920 |
22,500 |
0.05%
0.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):